EICHORCondition: Attention Deficit Hyperactivity Disorder · Sponsor: Shire
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Harmonex Neuroscience Research | Dothan, Alabama, United States | — |
| Advanced Research Center, Inc. | Anaheim, California, United States | — |
| Sun Valley Research Center, Inc. | Imperial, California, United States | — |
| Alliance Research | Long Beach, California, United States | — |
| PCSD Feighner Research | San Diego, California, United States | — |
| Homestead Medical Research | Homestead, Florida, United States | — |
| Clinical Neuroscience Solutions, Inc. | Jacksonville, Florida, United States | — |
| Care Research Center, Inc. | Miami, Florida, United States | — |
| Clinical Neuroscience Solutions, Inc. | Orlando, Florida, United States | — |
| AMR Conventions Research, Ltd | Naperville, Illinois, United States | — |
| Collective Medical Research LLC | Prairie Village, Kansas, United States | — |
| Qualmedica Research, LLC | Bowling Green, Kentucky, United States | — |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04085172